Soluble fms-Like Tyrosine Kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Powers, Robert W ^a   Jeyabalan, Arun ^a   Clifton, Rebecca G ^b   van Dorsten, Peter ^c   Hauth, John C ^d   Klebanoff, Mark A ^e   Lindheimer, Marshall D ^f   Sibai, Baha ^g   Landon, Mark ^h   Miodovnik, Menachem ⁱ  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^h THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENIC FACTOR; ENDOGLIN; PLACEBO; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; HYPERTENSION; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE PREGNANCY; PATHOGENESIS; PREECLAMPSIA; PREGNANT WOMAN; THIRD TRIMESTER PREGNANCY; BLOOD; PREGNANCY;

ADULT; ANGIOGENESIS INDUCING AGENTS; ANTIGENS, CD; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, CELL SURFACE;

EID: 78149431733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013263     Document Type: Article

References (17)

1. Roberts JM, Funai EF (2009) Pregnancy-Related Hypertension. In: Creasy RK, Resnik R, Iams JD, Lockwood CJ, Moore TR, eds. Maternal Fetal Medicine. Sixth Edition ed. Philadelphia: W. B. Saunders. pp 651-688.
2. Duley L (1992) Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. British Journal of Obstetrics & Gynaecology 99: 547-553.
3. Goldenberg RL, Rouse DJ (1998) Prevention of premature birth. New England Journal of Medicine 339: 313-320.
4. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, et al. (1998) Lowdose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. New England Journal of Medicine 338: 701-705.
5. Maynard SE, Min JY, Merchan J, Lim KH, Li J, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation 111: 649-658.
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. New England Journal of Medicine 350: 672-683.
7. Powers RW, Roberts JM, Cooper KM, Gallaher MJ, Frank MP, et al. (2005) Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. American Journal of Obstetrics & Gynecology 193: 185-191.
8. Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, et al. (2006) Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. American Journal of Obstetrics & Gynecology 194: 1034-1041.
9. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New England Journal of Medicine 355: 992-1005.
10. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. New England Journal of Medicine 350: 672-683.
11. Romero R, Nien JK, Espinoza J, Todem D, Fu W, et al. (2008) A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. Journal of Maternal-Fetal & Neonatal Medicine 21: 9-23.
12. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, et al. (2004) First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. Journal of Clinical Endocrinology & Metabolism 89: 770-775.
13. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, et al. (2007) Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50: 137-142.
14. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, et al. (2007) Angiogenic factors for the prediction of preeclampsia in high-risk women. American Journal of Obstetrics & Gynecology 197: 244.e241-248.
15. Maynard SE, Moore Simas TA, Solitro MJ, Rajan A, Crawford S, et al. (2008) Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. American Journal of Obstetrics & Gynecology 198: 200.e201-207.
16. Sibai BM, Koch MA, Freire S, Pinto e Silva JL, Rudge MV, et al. (2008) Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? American Journal of Obstetrics & Gynecology 199: 268.e261-269.
17. Levine RJ, Esterlitz JR, Raymond EG, DerSimonian R, Hauth JC, et al. (1996) Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods. Controlled Clinical Trials 17: 442-469.